Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase 1, Open-label Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorasidenib (Primary) ; Lamotrigine
  • Indications Glioma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Agios Pharmaceuticals

Most Recent Events

  • 23 Sep 2020 Results assessing effect of multiple doses of vorasidenib on the pharmacokinetics of a single dose of lamotrigine in healthy participants, presented at the 2020 American College of Clinical Pharmacology Annual Meeting
  • 11 Oct 2019 Status changed from recruiting to completed.
  • 16 Sep 2019 Planned End Date changed from 1 Oct 2019 to 1 Sep 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top